

RADIATION FORUM

FRIDAY APRIL 28, 2023 8:00 AM – 12:00 PM

CO-CHAIRS : MICHAEL MCKENZIE AND SCOTT MORGAN
SENIOR INVESTIGATOR: WENDY PARULEKAR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To integrate current knowledge regarding molecular biology and new therapeutics in clinical trials evaluating radiotherapy
- To review relevant data from clinical studies evaluating radiotherapy interventions conducted by the Canadian Cancer Trials Group or its collaborators
- To integrate current statistical methodologies in clinical trial design
- To provide a learning environment supportive to investigators

8:00 am	Welcome and Introductions	M. McKenzie & S. Morgan
	<u><i>CCTG Intergroup Open Trials</i></u>	
8:05 am	S1827: A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation in Small-Cell Lung Cancer. BRC.8	J. Greenland
8:10 am	ANZUP 1801: Darolutamide to Augment Standard Therapy for Localized High-Risk Cancer of the Prostate (DASLHiCaP) – A Randomized Phase III Trial of Adding Darolutamide to Radiation and Androgen Deprivation Therapy In High Risk Clinically Localized Prostate Cancer. PR.22	S. Morgan
8:15 am	NRG BR007: A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer (DEBRA). MAC.28	V. Theberge
	<u><i>CCTG Led Open Trials</i></u>	
8:20 am	TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer. MA.39	V. Theberge
8:30 am	Phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer. PR.19	E. Vigneault
8:40 am	A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases CE.7	D. Roberge
8:50 am	A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma. HN.10	S. Bratman



9:00 am	Randomized Phase II Study of Cisplatin + RT vs Durvalumab + RT followed by Adjuvant Durvalumab vs Durvalumab + RT followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Ca (LA-OSCC). HN.9	K. Sultanem
9:10 am	A Phase II Study of Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER). EN.10	K. Han
9:20 am	PLATON: A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer. PR.20	P. Cheung
9:30 am	SPECT-CT Guided ELEctive Contralateral Neck Treatment (Select) for Patients with Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial. HN.11	A. Hosni
9:40 am	Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver cancer. HE.1	L. Dawson
9:55 am	Coffee Break	
	<i><u>Updates on CCTG Approved Studies Pending Activation</u></i>	
10:10 am	Optimizing Head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: A Phase III Trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study). HN.13	I. Poon
10:20 am	A Randomized Phase 3 Trial Comparing Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases. SC.29	A. Sahgal
10:30 am	Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT). PR.24	A. Loblaw
	<i><u>New Study Proposals</u></i>	
10:40 am	PR19 Proposed Amendment 3: A Randomized Phase II Trial Evaluating Stereotactic Body Radiotherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer	J. Helou
10:50 am	Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)	P. Cheung
11:00 am	Head and Neck Elective Dose and Volume De-Escalation	J. Tsai



- 11:10 am** Stereotactic boost and **SH**ort-course Radiation Therapy for HPV-associated OroPharynx Cancer (S₂HORT-OPC) Trial: Phase II Randomized Trial **H. Bahig**
- 11:20 am** Adaptive RadioTherapy for Locally Advanced HPV-associated OroPharynx Cancer (ART-OPC) **H. Bahig**
- 11:30 am** A Randomized Phase II Study of Hypofractionated versus Conventional Fractionation Radiotherapy in Post-operative Gynecological Cancers Evaluating Late Toxicities and Quality of Life (SPARTACUS III) **E. Leung**
- 11:40 am** Pneumonitis Prevention Protocol using Pentoxifylline and α-tocopherol - P4-PACIFIC **S. Raman and P. Wong**
- 12:00 pm** Meeting Adjourned

